Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This Trial is Conducted in Europe and the United States of America. The Aim of This Trial is to Investigate Single Dose Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A.

NCT02920398 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02920398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02920398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This Trial is Conducted in Europe and the United States of America. The Aim of This Trial is to Investigate Single Dose Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A.
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
October 4, 2016
Completion date
April 7, 2017
Enrollment
21 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, haemophilia a